|
 |
| AGTC EMPLOYEES |
|
 |
 Dr.
Jeffrey Chulay, Chief Medical Officer and Vice President of Regulatory Affairs
Dr. Chulay brings broad medical and regulatory expertise to the Company. He joined AGTC in 2007 from AlphaVax, where as Senior Vice President and Chief Medical Officer he led successful clinical trial programs of recombinant viral vector vaccines for cytomegalovirus and influenza. Prior to joining AlphaVax, Dr. Chulay was a Principal Clinical Program Head in HIV and Opportunistic Infections at GlaxoSmithKline and was responsible for bringing two anti-infective drugs to market. He previously served as Chief of the Department of Immunology at the Walter Reed Army Medical Institute of Research (WRAIR) and Chief of the Virology Division at the U.S. Army Research Institute of Infectious Disease (USAMRIID). Dr. Chulay earned a medical degree from Northwestern University Medical School and a degree in tropical medicine and hygiene from the London School of Hygiene and Tropical Medicine. He served his residency at Cleveland Metropolitan General Hospital and was a fellow in Infectious Disease at WRAIR. He has been a member of the Institute of Medicine Committee on Prevention and Control of Malaria, published 100 papers in peer-reviewed journals and is a reviewer for several leading medical journals. |
 |
Teresa
Heal, Director of Finance
As Director of Finance, Teresa has worked more than twenty years in accounting, with fourteen years in senior management and the last thirteen years in healthcare, research and development. She has assisted the Company in raising more than $20M in the last four years and established control and audit procedures to maximize risk management. Prior to AGTC, Teresa spent eight years as Treasurer and Controller for a regional medical group where she centralized accounting, insurance and administration for fourteen locations, raising collections and lowering expenses and established strategic cash planning, investment and capital improvement policy. Prior to this position, her experience includes seven years in public accounting, a lead role in a merger and acquisition transaction as well as expertise in growing accounting departments for expanding needs. She graduated summa cum laude with a B.A. in Business Administration and Accounting and holds an MBA in Management. She is founder and President of the Florida Association of Bioscience Financial Officers, and serves in various local volunteer positions. |
 |
Dr.
David R. Knop, Director, Process Development
Dr.
David Knop joined AGTC
in 2002 and currently
heads the Process Development
group. He directs rAAV
and rHSV vector research
in the areas of production,
assay development,
downstream processing,
and purification. His
responsibilities include
hands-on bioreactor
cell culture, viral
vector production,
and downstream processing.
In addition, Dr. Knop
does fermentor plasmid
DNA production for
use in large scale
transfection procedures.
Dr. Knop earned his
B.S. (1996) and Ph.D.
(2002) degrees in Chemical
Engineering from Michigan
State University. His
doctoral research focused
on biocatalytic conversion
of carbohydrates to
fine and ultrafine
chemicals used as pharmaceutical
intermediates. The
biocatalysis process
developed for shikimic
acid and quinic acid
production from glucose
resulted in two patents
and licensure by a
major pharmaceutical
entity. |
 |
Dr.
Darby Thomas, Scientist
II, Process Development
Darby joined AGTC’s Process Development group as a Scientist in July 2004. She has been responsible for transitioning the rAAV proprietary production methodologies into a fully-scalable suspension platform and for assay development to aid in characterization of AGTC’s rAAV vectors. In addition to her scientific work, Darby has been responsible for Project Management activities, such as assay transfer to CMOs, CTOs, and collaborators, in support of production and testing of CTM. Darby came to AGTC as an expert in herpes simplex virus (HSV-1) as a result of her post-doctoral research at the University of Pennsylvania School of Medicine, in the Department of Microbiology. Specifically, she researched both understanding the unusual stability of the HSV-1 LAT intron and applications of replication-selective HSV-1 mutants in cancer therapy. Darby’s virology training began with her Ph.D. thesis from the Baylor College of Medicine in Houston, Texas, in the Cell and Molecular Biology Graduate Program and the Department of Molecular Virology and Microbiology, where she identified human adenovirus type 9 genetic determinants required for mammary tumorigenesis. She also has a B.S. in Biology with Honors from the University of North Carolina at Chapel Hill. |
 |
Sue
Washer, President
and CEO
Sue
Washer, President and
CEO of AGTC, is an
experienced entrepreneur
with a strong scientific
and operational background.
She has a B.S. in biochemistry
from Michigan State
University and an MBA
from the University
of Florida where she
was one of the first
graduates from the
Business School’s Entrepreneurship
program. Sue has 10
years of pharmaceutical
management and research
experience from Abbott
Labs and Eli Lilly
as well as 11 years
of senior management
experience with entrepreneurial
firms in the Gainesville
area. Sue successfully
raised over $15M for
AGTC in their second
round of funding in
November of 2003. |
 |
Dr.
Guo-jie Ye, Director, Research
and Preclinical Development
Dr. Ye is responsible for
leading a group of
scientists in the development
of new viral vectors
for AAV-based gene
therapy products. Prior
to joining AGTC in
July, 2004, Dr. Ye
was a Senior Scientist,
Preclinical R&D of
MediGene Inc. at San
Diego, California (2001-2004).
After receiving his
Ph.D. in Protein Chemistry
from Shanghai Institute
of Organic Chemistry,
Chinese Academy of
Sciences, China, Dr.
Ye underwent his postdoctoral
trainings both in molecular
biology at Cornell
University Medical
College, and in molecular
genetics of herpes
simplex virus at the
University of Chicago. |
|
|
|
|
|
|
|
About Us
